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SObjectives: We sought to evaluate the efficacy and safety of a synthetic bioresorbable pleural sealant
(PleuraSeal; Covidien, Bedford, Mass) to treat air leaks after pulmonary resection.
Methods: Patients with air leaks after lung resection were randomized to treatment with pleural sealant on air
leak sites after standard methods of lung closure or standard lung closure only. The primary outcome variable
was the percentage of patients remaining air leak free until discharge. The secondary outcome variables were the
proportion of patients with successful intraoperative air leak sealing, time to last air leak, and durations of chest
tube drainage and hospitalization.
Results: The sealant group comprised 62 subjects, and the control group comprised 59 subjects. Most patients
(98.3%) underwent open lobectomy for bronchogenic carcinoma. The overall success rates for intraoperative air
leak sealing were as follows: sealant group, 71.0%; control group, 23.7% (P<.001). For grade 2 and 3 air leaks
(n¼ 77), the intraoperative sealing rates were as follows: sealant group, 71.7%; control group, 9.1% (P<.001).
More patients with grade 2 and 3 air leaks had their leaks remain sealed in the sealant group (43.5% vs 15.2%,
P ¼ .013). The median time from skin closure to last observable air leak was 6 hours (sealant group) versus 42
hours (control group, P ¼ .718). No treatment-related complications were reported. No differences in drainage
or hospitalization were observed.
Conclusions: In this multicenter study the pleural sealant was safe and effective treatment for intraoperative air
leaks after lung resection. Significantly fewer patients with surgically relevant intraoperative air leaks had post-
operative air leaks when the pleural sealant was applied. (J Thorac Cardiovasc Surg 2011;141:881-7)Despite the liberal use of stapling devices, intraoperative
pulmonary air leakage occurs in 75% of patients after elec-
tive pulmonary resection.1 Patients with prolonged air leaks
are at risk for serious complications, such as empyema. Pro-
longed air leaks might necessitate pleurodesis or even reop-
eration.2 Approaches to decrease the intensity and duration
of air leaks include a variety of techniques and sealants. A
Cochrane review that evaluated the effectiveness of sealants
in preventing or reducing postoperative air leaks after pul-
monary resection concluded that surgical sealants reduce
postoperative air leaks.3 However, the definitive role of
sealants in air leak treatment after lung surgery remains un-
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The Journal of Thoracic and Camany the sealant was used to prevent rather than treat air
leaks because few patients with air leaks were randomized.
PleuraSeal (Covidien, Bedford, Mass) is a synthetic,
polyethylene glycol (PEG)–based hydrogel sealant in-
tended for use in elective pulmonary resections as an ad-
junct to standard closure techniques. The sealant is fully
synthetic, more than 90% water, and has no human- or
animal-derived products. When applied, it forms an effec-
tive barrier that is tissue compliant, tissue adherent, and lu-
bricious. The material is absorbed in approximately 4 to 8
weeks, which is sufficient time to allow for healing. This
study evaluated the air-sealing efficacy of PleuraSeal on al-
veolar air leaks after open lobectomy or segmentectomy.MATERIALS AND METHODS
This was a prospective, multicenter, randomized, single-blind study. Pa-
tients older than 18 years whowere scheduled for elective lobectomy or an-
atomic segmental resection by means of open thoracotomy were eligible
for inclusion. Patients were screened within 6 weeks of the operation. Pre-
operative laboratory values could not exceed 1.5 mg/dL serum bilirubin,
120 IU/L alkaline phosphatase, 1.5 mg/dL creatinine, and 10,800/mm3
white blood cell count. Further preoperative exclusion criteria were a docu-
mented history of bleeding disorders, compromised immune system, prior
ipsilateral thoracotomy, active systemic or pulmonary infection, uncon-
trolled diabetes, and chronic steroid therapy (>4 weeks). Female patients
with childbearing potential required a negative pregnancy test result before
inclusion. All patients were required to provide written informed consent.
The study protocol was approved by the ethics committees of all therdiovascular Surgery c Volume 141, Number 4 881
FIGURE 1. Flow diagram of the multicenter pleural sealant study.
TABLE 1. Preoperative criteria for randomization: High versus low
risk
Preoperative criteria Score if absent Score if present
COPD 1 (FEV1 80) 0 1
COPD 2 (FEV1 50–80) 0 2
COPD 3 (FEV1<30–50) 0 3
COPD 4 (FEV1<30) 0 4
FEV1/FVC%<65% 0 1
Smoking (ever as a habit) 0 1
Emphysema 0 1
Preoperative chemotherapy* 0 1
Preoperative radiation therapy* 0 1
COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1
second; FVC, forced vital capacity. *Patients treated with neoadjuvant therapy/sur-
gery protocol.
Abbreviation and Acronym
PEG ¼ polyethylene glycol
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Declaration of Helsinki and good clinical practices.
The study was performed at 8 tertiary care medical centers in Europe:
University Hospital Leuven (Leuven, Belgium), Otto Wagner Hospital
(Vienna, Austria), VU-Medisch Centrum (Amsterdam, The Netherlands),
Universit€atsklinik–Landeskrankenhaus Innsbruck (Innsbruck, Austria),
University Hospital Zurich (Zurich, Switzerland), Ho^pital Erasme (Brus-
sels, Belgium), Papworth Hospital (Cambridge, United Kingdom), and
Medical Centre Rotterdam Zuid (Rotterdam, The Netherlands). This last
center was not able to enroll any patients. All participating surgeons
were qualified thoracic surgeons. At an investigator meeting, the protocol
was discussed, and investigators were trained to use the sealant.
The primary end point was the proportion of patients remaining air leak
free from the time of skin closure to hospital discharge. Secondary end
points were the proportion of patients with successful intraoperative air
leak sealing, time from skin closure to last observable air leak, duration
of chest tube drainage, and length of hospitalization. All serious adverse
events, treatment-related events, unanticipated adverse device effects,
and predefined complications were reported.
All pulmonary resections were performed according to the institutional
standard-of-care procedures. The fissures were opened in a nonthoraco-
scopic way by opening the fissure on the artery and then stapling or suturing
the incomplete fissure.
After hemostasis was achieved and standard lung tissue closure was
completed to the investigator’s satisfaction, eligible patients underwent
an air leak assessment by means of lung submersion leak testing. Warm
sterile saline solution or water was instilled into the thorax in a sufficient
quantity to allow for submersion of the cut or dissected lung surfaces. Al-
though mechanical ventilation was maintained with an end-inspiratory air-
way pressure of approximately 20 to 25 cm H2O, all sites of surgical
dissection and surgical manipulation were assessed for leaks and graded
as reported by Macchiarini and colleagues.4 The location, type (staple
line, suture line, area of adhesion, and area of dissection), and grade of
each air leak were recorded.
During the operation, patients were deemed ineligible for further par-
ticipation if they underwent pneumonectomy or sleeve resection, if they
had severe adhesions, or if hemostasis could not be obtained. Patients
with simple adhesions limited to the lobe that had to be removed were
included. Patients without intraoperative air leaks were ineligible for ran-
domization.
The flow diagram of the study is shown in Figure 1. Patients who pre-
sented with an intraoperative air leak were allowed to be treated with addi-
tional standard closure techniques before randomization if the investigator
determined it feasible. Patients were then randomly assigned on a 1:1 basis
to either the pleural sealant group or control group. Randomization was
blocked by investigative site. Randomization was also stratified by a com-
bined preoperative/intraoperative air leak risk assessment score (high-risk
score [>5] versus low-risk score [5]) to ensure balance between the 2
treatment groups. This risk assessment score was based on preoperative
and intraoperative parameters (Tables 1 and 2).
Before study initiation, a treatment randomization scheme was gener-
ated, and randomization envelopes were provided to each site. Patients
were randomized within their risk stratum by opening the next sealed en-
velope (labeled either high risk or low risk) in the operating room.
After resection, 2 chest drains were inserted. Postoperatively, chest
tubes were run on 20 cm H2O suction for up to 18 hours and then switched
to a water seal. The chest drainage system was examined by trained staff at882 The Journal of Thoracic and Cardiovascular Surg12-hour intervals. Postoperative air leaks were defined as the presence of
a single air bubble in the chest drains during the course of normal or forced
expiration (coughing). The chest tubes were removed when there was no
evidence of an air leak and the drainage was less than 300 mL in a 24-
hour period. Chest radiographs were taken on the first postoperative day,
within 8 hours after chest tube removal, and at discharge. Vital signs and
renal and hepatic function were assessed immediately after the operation
and at the follow-up evaluation 30 days postoperatively.
All statistical tests were 2-sided at the 5% significance level, unless oth-
erwise indicated. The statistical analysis was performed with SAS soft-
ware, version 9.1 or higher (SAS Institute, Inc, Cary, NC). The primary
effectiveness end point was defined as the proportion of patients remaining
air leak free from the time of skin closure to hospital discharge. These pro-
portions were determined and compared with a 2-sided Fisher’s exact test.
The time from skin closure to the last observable air leak (in hours) was
evaluated. The Kaplan–Meier method was used to obtain estimated median
time to leak-free status, and the log-rank test was used to compare the 2
treatments. The median duration of chest tube drainage and hospitalization
was compared by using the 2-sample t test.ery c April 2011
TABLE 2. Intraoperative criteria for randomization: High versus low
risk
Intraoperative criteria Score ¼ 0 Score ¼ 1 Score ¼ 2
Adhesions Absent Present (any) NA
Tissue Normal Fragile* NA
Extent of operation Typical Extensivey NA
No. of leak sites 1–2 3–6 >6
NA, Not applicable. *Extensive bullous disease; fibrotic noncompliant tissue; thin pa-
renchyma, low blood vessel density, or both; or torn lung. yPatient requires complete
intrapleural resection of adhesions or extensive intrafissural dissection in subjects
with incomplete pulmonary fissures or requires surgical resection of more than 1
lobe (eg, lobectomy and wedge resection or bilobectomy).
TABLE 3. Baseline and intraoperative patients’ characteristics
Characteristics
Pleural sealant
group (n ¼ 62)
Control
group
(n ¼ 59)
P
value*
Age (y) .463
Mean (SD) 61.5 (9.1) 62.8 (10.8)
Range (minimum–maximum) 35–77 25–81
Sex, no. (%) .710
Female 26 (41.9) 22 (37.3)
Male 36 (58.1) 37 (62.7)
BMI (kg/m2) .563
Mean (SD) 25.86 (4.73) 26.35 (4.55)
Range (minimum–maximum) 17.7–41.6 18.8–41.0
Nicotine use, no. (%) .719
History 31 (50.0) 34 (57.6)
Current 22 (35.5) 17 (28.8)
Ethnic origin, no. (%) .553
White 61 (98.4) 55 (93.2)
Other 1 (1.6) 4 (6.8)
Indication for operation, no. (%)
Primary lung cancer 62 (100.0) 57 (96.6) .236
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ant and control groups were assumed to be 0.40 (40%) and 0.15 (15%),
respectively. Based on the anticipated tissue closure success rates and as-
suming a 1:1 (pleura; sealant/control) randomization ratio, 56 patients
per treatment were required to achieve 80% power (a ¼ .05, 2-tailed,
Fisher’s exact test), resulting in a total of 112 patients. To account for ap-
proximately 6% anticipated patient withdrawals, an additional 8 patients
were to be enrolled, for a total of 120 randomized patients, with approxi-
mately 60 per group.
Other 0 (0.0) 2 (3.4)
Concomitant pulmonary
diagnosis, no. (%)
None 27 (43.5) 34 (57.6) .147
Emphysema 16 (25.8) 9 (15.3) .181
Asthma 3 (4.8) 1 (1.7) .619
Silicosis 1 (1.6) 2 (3.4) .613
COPD 29 (46.8) 20 (33.9) .195
Chronic bronchitis 2 (3.2) 1 (1.7) 1.000
Previous pulmonary
therapy, no. (%)
Radiation therapy 5 (8.1) 2 (3.4) .440
Chemotherapy 10 (16.1) 4 (6.8) .154
Total risk score (preoperative
and intraoperative)
3.9  2.0 3.4  1.6 .160
Type of procedurey 1.000
Lobectomy 61 (98.4) 58 (98.3)
Segmentectomy 1 (1.6) 1 (1.7)
Resection location, no. (%) .458
Left lung 21 (33.9) 24 (40.7) .755
Right lung 41 (66.1) 35 (59.3) .234
BMI, Bodymass index;COPD, chronic obstructive pulmonary disease. *P value from
Fisher’s exact test for categorical variables and from the 2-sample t test for continuous
variables. yA patient can have more than 1 procedure, and therefore the percentages
might sum to more than 100%.RESULTS
Between January 28, 2008, and October 21, 2008, 161
patients consented to potential study participation, of
whom 121 were randomized to the sealant group (n ¼ 62)
or the control group (n ¼ 59). Of these, 120 patients (61
in the sealant group and 59 in the control group) completed
the 30-day follow-up. Among the 40 nonrandomized pa-
tients, 5 did not meet the preoperative eligibility criteria af-
ter providing informed consent. The other 35 did not meet
the intraoperative eligibility criteria. The main reasons for
intraoperative exclusion were absence of an intraoperative
air leak (15/156) or surgical procedures other than open lo-
bectomy or anatomic segmentectomy (21/156).
Table 3 shows the baseline demographic and intraopera-
tive characteristics. Overall, the sealant and control groups
were well balanced. The indication for pulmonary resection
was lung cancer in most of the cases (98.4%). In 98% of
patients, an open lobectomy was performed. In 62% of pa-
tients, the lobectomy was on the right side, with upper lo-
bectomy the most frequent. Estimated total length of
staples and sutures was similar between groups. Additional
prerandomization standard closure techniques were staples
in 9% (pleural sealant group) and 3.4% (control group) and
sutures in 7.3% (pleural sealant group) and 6.8% (control
group). Other sealants were not used.
The mean duration of surgical intervention was not statis-
tically different between the sealant and control groups:
2.5 hours (range, 1.4–4.6 hours) versus 2.35 hours (range,
1.0–4.2 hours), respectively.
Themean total preoperative risk scorewas significantlydif-
ferent between groups (sealant, 3.0; control, 2.6; P ¼ .039),
which suggests that the sealant group was a higher-risk popu-
lation. There was no statistical difference between groups inThe Journal of Thoracic and Cathe intraoperative risk score or the total combined risk score
(preoperative and intraoperative). According to the risk strat-
ification performed, 86% of patients were scored lower risk
and 14% were scored higher risk.
Grade 1 intraoperative air leaks were observed before
randomization in 26% of the sealant group versus 44%
of the control group. Consequently, grade 2 and 3 air leaks
were observed in 74% of the sealant group versus 56% of
the control group. These differences were not statistically
significant (P ¼ .077). In the pleural sealant group 44.8%rdiovascular Surgery c Volume 141, Number 4 883
FIGURE 3. Percentage of patients with intraoperative air leak sealing in
the pleural sealant and control groups.
General Thoracic Surgery De Leyn et al
G
T
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with 46.6% in the control group.
Primary End Point
In the sealant group 41.9% of patients remained air leak
free until discharge versus 30.5% in the control group
(P¼ .257). The pleural sealant was found to be more effec-
tive in sealing grade 2 and 3 air leaks than control treatment
(43.5% success vs 15.2% success, respectively; P ¼.013).
The difference between treatments on grade 1 leaks was not
significant (Figure 2).
Secondary End Points
The pleural sealant effectively sealed intraoperative air
leaks, as shown in Figure 3. Overall, significantly more pa-
tients had successful intraoperative sealing after pleural
sealant application than patients who received the control
standard of care (71.0% vs 23.7%, P<.001). In the low-
risk population the pleural sealant stopped air leaks in sig-
nificantly more patients than control standard of care
(70.6% vs 24.5%, P< .001). In the high-risk population
the pleural sealant was more effective than control standard
of care, but the difference was just short of statistical signif-
icance (72.7% vs 16.7%, P ¼ .050).
Before pleural sealant application, 16 (25.8%) patients
had grade 1 air leaks, 42 (67.7%) had grade 2 air leaks,
and 4 (6.5%) had grade 3 air leaks. Application of the pleu-
ral sealant completely sealed the air leaks in 44 (71%) pa-
tients; in 14 (22.6%) patients the air leak diminished to
grade 1, and in 4 (6.5%) patients it decreased to grade 2.
The median time from skin closure to the last observable
air leak was shorter in patients treated with the pleural seal-
ant than in those who received standard of care, but the dif-
ference was not statistically significant (6 vs 30 hours,
P ¼ .790). The median duration of chest tube drainage
was not statistically different between the sealant and con-
trol groups (93.7 hours [range, 22.7–838.9 hours] vs 94.1
hours [range, 17.7–478.7 hours], P ¼ .559).FIGURE 2. Primary end point: percentage of patients with grade 1 and
grade 2 or 3 air leak who remained air leak free until discharge in the pleu-
ral sealant and control groups.
884 The Journal of Thoracic and Cardiovascular SurgThe median length of hospitalization was not statistically
different between the sealant and control groups (312 hours
[range, 144–3144 hours] vs 288 hours [range, 120–2040
hours], P ¼ .292). Persistent air leaks were the reason for
a delayed hospital discharge in 4.8% of the pleural sealant
group and 11.9% of the control group (P ¼ .303).
The incidence of predefined complications or serious ad-
verse events was similar between the sealant and control
groups (35.5% vs 23.7%, P ¼ .170), as shown in Tables
4 to 6. There were no deaths. There were no treatment-
related adverse events noted for either treatment group.
The reported complications were not unexpected for the
surgical procedure or the underlying cancer. No clinical
or laboratory evidence of adverse events attributable to
the application of the sealant was observed.
In the vast majority of patients, the lung was fully ex-
panded at all postoperative time points. At discharge, the
lung was fully expanded in 97.4% of the pleural sealant
group and 97.3% of the control group. Lung expansion
and residual space in patients with pneumothorax was com-
parable between groups.
DISCUSSION
Air Leak Control
Air leaks are a common problem after lobectomy for lung
cancer and are the major cause of prolonged hospitalization.
Prolonged air leak occurs in 15% of patients undergoing
lobectomy. Although air leaks can heal conservatively,
some patients will have empyema, might need a reinterven-
tion, or both.2 A study conducted by Brunelli and co-
workers5 evaluated air leaks after lobectomy. On the first
postoperative day, 28.8% of patients had air leaks. Pro-
longed air leak, defined as lasting more than 7 days, was
present in 15.6% of patients, and 3.4% of patients stillery c April 2011
TABLE 4. Summary of reported events (safety population)
Parameter
Pleural sealant group
(n ¼ 62), no. (%)
Control group
(n ¼ 59), no. (%) P value*
Subjects with any predefined complication or SAE 22 (35.5) 14 (23.7) .170
Subjects with any SAE 16 (25.8) 11 (18.6) .388
Subjects with any predefined complication 9 (14.5) 6 (10.2) .584
Subjects with any unanticipated adverse device effect 0 (0.0) 0 (0.0) —
Subjects with any treatment-related reported event —
Yes 0 (0.0) 0 (0.0) —
No 56 (90.3) 57 (96.6) .274
Unable to determine 6 (9.7) 2 (3.4) .274
SAE, Serious adverse event. *P value based on Fisher’s exact test.
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longed air leak had significantly higher morbidity compared
with those without prolonged air leak, with a significantly
higher incidence of empyema and pneumonia.TABLE 5. Serious adverse events (subject level)
System organ
class/preferred term
Pleural sealant
group (n ¼ 62),
no. (%)
Control group,
(n ¼ 59),
no. (%)
P
value*
Infections and Infestations 5 (8.1) 3 (5.1) .718
Empyema 2 (3.2) 0 (0.0)
Pneumonia 2 (3.2) 1 (1.7)
Bronchopneumonia 0 (0) 1 (1.7)
Wound infection 1 (1.6) 1 (1.7)
Respiratory, thoracic,
and mediastinal disorders
9 (14.5) 5 (8.5) .397
Acute respiratory
distress syndrome
1 (1.6) 0 (0.0)
Atelectasis 0 (0.0) 1 (1.7)
Bronchopleural fistula 1 (1.6) 0 (0.0)
Pleural effusion 1 (1.6) 0 (0.0)
Pneumothorax 5 (8.1) 1 (1.7)
Hydropneumothorax 1 (1.6) 2 (3.4)
Pulmonary embolism 0 (0.0) 1 (1.7)
Emphysema 1 (1.6) 0 (0.0)
Cardiac disorders 2 (3.2) 1 (1.7) 1.000
Cardiac arrest 0 (0.0) 1 (1.7)
Cardiac failure chronic 1 (1.6) 0 (0.0)
Ventricular fibrillation 1 (1.6) 0 (0.0)
Nervous system disorders 1 ( 1.6) 0 (0.0) 1.000
Ischemic stroke 1 (1.6) 0 (0.0)
Skin and subcutaneous
tissue disorders
1 (1.6) 0 (0.0) 1.000
Subcutaneous emphysema 1 (1.6) 0 (0.0)
Vascular disorders 0 (0.0) 1 (1.7) .488
Peripheral ischemia 0 (0.0) 1 (1.7)
General disorders and
administration site
conditions
2 (3.2) 2 (3.4) 1.000
Fatigue 0 (0.0) 2 (3.4)
Pain 2 (3.2) 0 (0.0)
Note: A patient can have more than 1 event. If a patient had multiple occurrences of
the same serious adverse event, only the first occurrence was counted. *P value based
on Fisher’s exact test.
The Journal of Thoracic and CaPreventing air leakage is important for optimal outcomes
and is controlled in part by meticulous thoracic surgical
techniques, pleural tenting in upper lobectomy, and use of
buttressed staplers in emphysematous tissue.6 Standard
methods of closure, including sutures and staples, have
the disadvantage of causing further trauma to the lung tis-
sue, which can increase the air leak severity.Surgical Sealants
There has been great interest in the use of surgical seal-
ants (glue) to seal air leaks after lung resection. The ideal
lung sealant material needs to be sufficiently strong and ad-
herent to withstand pressures of 30 to 40 cm H2O that are
normally present in inflated lungs. A sealant material should
also be flexible and compliant to accommodate lung volume
changes. Sealants should bond rapidly to lung tissue and be
unaltered by underlying blood or moisture. The sealant
needs to be locally nonirritating, systemically nontoxic,
and nonantigenic. Lastly, the ideal sealant should be readily
available in the operating room and easy to use.
Recently, a new synthetic tissue sealant has been devel-
oped with mechanical characteristics approximating these
qualities. The pleural sealant used in this study rapidly poly-
merizes (within 3 seconds) to form a biocompatible absorb-
able PEG hydrogel. The hydrogel is simple to prepare and
easy to apply. Because it is synthetic, the pleural sealant
has no potential for transmitting blood-borne pathogens.TABLE 6. Rates of predefined complications (safety population)
Complication
Pleural sealant
group (n ¼ 62),
no. (%)
Control group
(n ¼ 59), no. (%)
P
value*
Colitis/gastroenteritis 3 (4.8) 0 (0.0) .244
Urinary tract infection 1 (1.6) 0 (0.0) 1.000
Pleural empyema 2 (3.2) 0 (0.0) .496
Wound infection 2 (3.2) 1 (1.7) 1.000
Atrial fibrillation 2 (3.2) 4 (6.8) .432
Pulmonary embolism 0 (0.0) 1 (1.7) .488
Note: A patient can have more than 1 event. If a patient had multiple occurrences of
the same complication, only the first occurrence was counted. Predefined complica-
tions that are serious adverse events are included. *P value based on Fisher’s exact
test.
rdiovascular Surgery c Volume 141, Number 4 885
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water content results in a gel with a low durometer value and
favorable elastic properties that is ideal for lung applications.
Air Leak Clinical Trials
A recent Cochrane study evaluated the use of sealants for
preventing air leaks after pulmonary resection.3 Between
1990 and 2008, 16 trials with 1642 randomized patients
were included. Several types of sealants were used. In 6 trials
postoperative air leaks were significantly reduced.7-12 Three
trials showed a significant reduction in time to chest drain
removal.7,10,13 In 3 trials there was a significant reduction
in length of hospital stay.10,13,14 However, these trials
differed in several ways. Only 4 trials were multicenter
studies.9,12,14,15 In only 6 trials were patients with
intraoperative air leaks randomized.8,10,12-14,16 In other
trials staple lines and cut surfaces of lung parenchyma
were routinely covered with the sealant regardless of the
presence of air leaks.
Since the Cochrane study, 1 study on the use of sealants
for air leaks has been published.17 A single-center study
evaluated the role of Coseal Surgical Sealant (PEG; Baxter
BioSurgery, Deerfield, Ill) after wedge resection/lobec-
tomy/segmentectomy in patients with grade 2 and 3 air
leaks. Intraoperative air leaks were significantly more
sealed, and there was a significant reduction in air leak du-
ration. However, there was no effect on chest drain duration
or hospitalization.
Results from single-center studies cannot always be re-
peated in multicenter studies because many confounding
factors can interfere and standard practices vary in each in-
stitution. A single-center study evaluating the role of Tacho-
sil (equine-derived collagen patch coated with human
fibrinogen and thrombin; Nycomed, Zurich, Switzerland,
and Baxter BioSurgery) found no significant effect on the
percentage of air leak–free patients on the first and second
postoperative days. However, a significant reduction in
time to chest drain removal and hospitalization time was
found.13 In a multicenter study the use of the same sealant
after lobectomy had no significant effect on chest drain du-
ration or hospital stay.12
Air leaks can be measured in different ways. Nowadays,
systems with digital airflow sensors are available that are
more accurate in measuring postoperative air leakage.
One study found no significant effect on the percentage of
air leak–free patients on the first and second postoperative
days after application of Tachosil.13 However, when postop-
erative air leakage was measured with the digital mass air-
flow sensor device, a significant reduction of air leak
volume was noted.
Pleural Sealant Multicenter European Study
In this prospective European study the use of the pleural
sealant for air leak treatment after pulmonary resection was886 The Journal of Thoracic and Cardiovascular Surganalyzed. Themajority of patients underwent lobectomy for
lung cancer. Patients were stratified into high-risk or low-
risk groups according to well-defined preoperative and in-
traoperative risk factors. In 71% of treated patients, the
pleural sealant completely sealed intraoperative air leaks,
and in the remaining patients intraoperative air leaks be-
came less severe. The sealant effect was statistically signif-
icant compared with that seen in the control group.
Postoperatively, 41.9% of sealant-treated patients and
30.5% of patients receiving standard care remained air
leak free, but this effect did not reach statistical signifi-
cance. Among patients with grade 2 and 3 intraoperative
air leaks, significantly more sealant-treated patients than
control patients remained air leak free until discharge
(43.5% vs 15.2%, P ¼ .013). There was a clear trend to-
ward reduced duration of air leak in the pleural sealant
group (6 hours) compared with the control group (30 hours),
but statistical significance was not attained. We observed no
significant effect on chest drain or hospitalization durations.
However, the length of hospitalization was highly variable
by site.
Somewhat to our surprise, the standard care control group
had a higher-than-expected rate of intraoperative (23.7%)
and postoperative (30.5%) air leak control. The choice of
a 15% success rate for the primary end point for the control
group was based on the best available information at the
time of the design of the study. A study by Allen and asso-
ciates14 had reported that 14% of control patients receiving
the standard of care remained leak free after pulmonary re-
section. The choice of a 40% success rate for the treatment
group was based on available animal data and turned out to
be reasonably accurate. The lack of statistical significance
for the primary end point might well be due to insufficient
statistical power. With the planned sample size of 60 sub-
jects per treatment group, the statistical power was only
19.9% to reject the null hypothesis of no difference in the
true treatment percentages using a 2-sided Fisher’s exact
test, if the true treatment percentages were as observed in
this study. To obtain 80% power would have required
a much larger study with 295 subjects per treatment group.
There were no specific complications or morbidity that
appeared to result from the use of the sealant. There was
no difference noted in the presence of pneumothorax or in
the expansion of the remaining lung. The pleural sealant ap-
pears to be safe for patients and is easy for surgeons to apply.
We believe that the strengths of this study are that it is
a multicenter study and that all patients had open lobectomy
or segmental resection with intraoperative proof of air leaks
that were not suitable for correction by means of resuturing
or restapling. A limitation of our study is the interobserver
variability in assessing the presence of an air leak. By using
digital chest drainage units with airflow sensors, the inter-
observer variability might be even more reduced, and this
might be useful for future studies.ery c April 2011
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SOur study also shows that in Europe hospital stay after lo-
bectomy is not primarily determined by the presence of air
leaks. Other (medical, cultural, and social) reasons seem to
have a major effect on length of hospital stay. However, be-
cause health care financing has become more and more
care-program driven with a fixed payment per pathology,
the evolution of shorter hospitalization after pulmonary re-
section is to be expected in Europe. At that time, it is likely
that duration of air leakage will have a significant effect on
hospitalization time, and sealants like the pleural sealant
tested in this study can play an important role in achieving
that goal.
In this multicenter European study the use of the pleural
sealant significantly reduced intraoperative air leaks after
lobectomy. In patients with clinically significant air leaks
(grade 2 and 3), significantly fewer patients had postopera-
tive air leaks when treated with the pleural sealant. How-
ever, this did not result in a significantly shorter duration
of chest drain use and length of hospital stay. We conclude
that the pleural sealant used in this study is easy to use, safe,
and effective in treating patients with clinically relevant air
leaks after pulmonary resection.References
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